The global pancreatic cancer precision medicine market size is anticipated to reach USD 1.88 billion by 2030, registering a CAGR of 19.2% during the forecast period, according to a new report by Grand View Research, Inc. The pancreatic cancer precision medicine industry experiences growth due to the increasing adoption of targeted therapies and immunotherapies, which enhanced survival rates and minimized side effects. Advanced diagnostic tools, including liquid biopsies and molecular profiling, improved early detection and treatment efficacy. This shift towards precision medicine facilitated more effective, individualized treatment strategies.
Technological progress, specifically the integration of next-generation sequencing and bioinformatics, facilitated the discovery of new therapeutic targets, enabling more effective drug design. Pharmaceutical companies, academic institutions, and government organizations increased their investments, supporting the development of innovative therapies. Initiatives such as the PanCAN grants program demonstrated a commitment to funding pancreatic cancer research, driving market growth.
The rising incidence of pancreatic cancer, influenced by lifestyle factors and an aging population, created a higher demand for specialized treatments. In 2024, Cancer Australia estimated 4,641 new pancreatic cancer cases were diagnosed in the country. This growing prevalence propelled market growth as healthcare providers sought more effective options. Furthermore, strategic collaborations between pharmaceutical companies and research institutions and regulatory support further accelerated market growth.
Request a free sample copy or view report summary: Pancreatic Cancer Precision Medicine Market Report
Based on therapeutic approach, targeted therapy dominated the market and accounted for a share of 56.0% in 2024, owing to by advancements in personalized treatment and genomic profiling.
Chemotherapy-precision combinations, on the other hand, is expected to grow at the fastest CAGR of over the forecast period.
Based on diagnostic technology, genomic testing led the market and accounted for 40.8% in 2024. Its role in identifying actionable mutations proved essential for personalized treatment.
Liquid biopsies, a minimally invasive method for early detection via ctDNA and CTC analysis, are projected to grow at the fastest CAGR of 20.3% over the forecast period, driven by improved patient outcomes.
The increasing adoption of targeted therapies and immunotherapies, coupled with advanced diagnostics, fuels market growth by enhancing survival rates and tailoring effective precision medicine strategies.
North America dominated the global pancreatic cancer precision medicine industry with a 42.9% revenue share, driven by high incidence rates and demand for effective treatments.
Market players operating in the pancreatic cancer precision medicine industry include AstraZeneca; Pfizer Inc.; Novartis AG; Amgen Inc.; F. Hoffmann-La Roche Ltd; Bayer AG; Eli Lilly and Company; Merck & Co., Inc.; Teva Pharmaceutical Industries Ltd; PharmaCyte Biotech, Inc.; Genentech, Inc.; Guardant Health; Illumina, Inc.; Thermo Fisher Scientific Inc.; FOUNDATION MEDICINE, INC.
In August 2024, Illumina Inc. launched a new oncology menu for its NovaSeq X Series customers, expanding comprehensive genomic profiling at lower costs and greater scale for customers worldwide.
Grand View Research has segmented the global pancreatic cancer precision medicine market based on therapeutic approach, diagnostic technology, and region:
Pancreatic Cancer Precision Medicine Therapeutic Approach Outlook (Revenue, USD Million, 2018 - 2030)
Targeted therapy
PARP inhibitors
Monoclonal antibodies
Small molecule inhibitors - EGFR inhibitors, KRAS inhibitors
Immunotherapy
Immune checkpoint inhibitors - PD-1 inhibitors, PD-L1 inhibitors
Cancer vaccines - GVAX, Algenpantucel-L
Adoptive T-Cell therapies - CAR-T therapies
Chemotherapy-precision combinations
Other therapeutic approaches
Pancreatic Cancer Precision Medicine Diagnostic Technology Outlook (Revenue, USD Million, 2018 - 2030)
Genomic testing
Molecular diagnostics
Liquid biopsy
Biomarker-based companion diagnostics
Others (Immunohistochemistry (IHC), proteomics, mass spectrometry)
Pancreatic Cancer Precision Medicine Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Thailand
South Korea
Australia
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Pancreatic Cancer Precision Medicine Market
AstraZeneca
Pfizer Inc.
Novartis AG
Amgen Inc.
F. Hoffmann-La Roche Ltd
Bayer AG
Eli Lilly and Company
Merck & Co., Inc.
Teva Pharmaceutical Industries Ltd
PharmaCyte Biotech, Inc.
Genentech, Inc.
Guardant Health
Illumina, Inc.
Thermo Fisher Scientific Inc.
FOUNDATION MEDICINE, INC.
"The quality of research they have done for us has been excellent..."